Zevra Therapeutics (ZVRA) Other Gross PP&E Adjustments: 2014-2025
Historic Other Gross PP&E Adjustments for Zevra Therapeutics (ZVRA) over the last 7 years, with Sep 2025 value amounting to -$1.7 million.
- Zevra Therapeutics' Other Gross PP&E Adjustments rose 77.42% to -$1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.9 million, marking a year-over-year increase of 41.55%. This contributed to the annual value of -$4.7 million for FY2024, which is 22.15% down from last year.
- Per Zevra Therapeutics' latest filing, its Other Gross PP&E Adjustments stood at -$1.7 million for Q3 2025, which was up 22.32% from -$2.1 million recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' Other Gross PP&E Adjustments ranged from a high of -$698,000 in Q3 2023 and a low of -$7.3 million during Q3 2024.
- Over the past 3 years, Zevra Therapeutics' median Other Gross PP&E Adjustments value was -$3.8 million (recorded in 2023), while the average stood at -$3.9 million.
- As far as peak fluctuations go, Zevra Therapeutics' Other Gross PP&E Adjustments tumbled by 948.71% in 2024, and later spiked by 77.42% in 2025.
- Quarterly analysis of 5 years shows Zevra Therapeutics' Other Gross PP&E Adjustments stood at -$3.1 million in 2021, then rose by 6.47% to -$2.9 million in 2022, then decreased by 29.94% to -$3.8 million in 2023, then declined by 22.15% to -$4.7 million in 2024, then spiked by 77.42% to -$1.7 million in 2025.
- Its Other Gross PP&E Adjustments was -$1.7 million in Q3 2025, compared to -$2.1 million in Q2 2025 and -$6.5 million in Q1 2025.